Literature DB >> 32016013

The PEMBRO-RT phase II randomized trial and the evolution of therapy for metastatic non-small cell lung cancer: a historical perspective.

Steven E Schild1.   

Abstract

Entities:  

Year:  2019        PMID： 32016013      PMCID： PMC6976434          DOI： 10.21037/atm.2019.11.42

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Authors:  Simon J Dovedi; Eleanor J Cheadle; Amy L Popple; Edmund Poon; Michelle Morrow; Ross Stewart; Erik C Yusko; Catherine M Sanders; Marissa Vignali; Ryan O Emerson; Harlan S Robins; Robert W Wilkinson; Jamie Honeychurch; Timothy M Illidge
Journal:  Clin Cancer Res       Date:  2017-05-22       Impact factor: 12.531

3.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Authors:  Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

4.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.

Authors:  Yasushi Nagata; Kenji Takayama; Yukinori Matsuo; Yoshiki Norihisa; Takashi Mizowaki; Takashi Sakamoto; Masato Sakamoto; Michihide Mitsumori; Keiko Shibuya; Norio Araki; Shinsuke Yano; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

5.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

6.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

7.  A new scoring system for predicting survival in patients with non-small cell lung cancer.

Authors:  Steven E Schild; Angelina D Tan; Jason A Wampfler; Helen J Ross; Ping Yang; Jeff A Sloan
Journal:  Cancer Med       Date:  2015-06-23       Impact factor: 4.452

8.  Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Authors:  Christina Twyman-Saint Victor; Andrew J Rech; Amit Maity; Ramesh Rengan; Kristen E Pauken; Erietta Stelekati; Joseph L Benci; Bihui Xu; Hannah Dada; Pamela M Odorizzi; Ramin S Herati; Kathleen D Mansfield; Dana Patsch; Ravi K Amaravadi; Lynn M Schuchter; Hemant Ishwaran; Rosemarie Mick; Daniel A Pryma; Xiaowei Xu; Michael D Feldman; Tara C Gangadhar; Stephen M Hahn; E John Wherry; Robert H Vonderheide; Andy J Minn
Journal:  Nature       Date:  2015-03-09       Impact factor: 49.962

9.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Authors:  Edward B Garon; Matthew D Hellmann; Naiyer A Rizvi; Enric Carcereny; Natasha B Leighl; Myung-Ju Ahn; Joseph Paul Eder; Ani S Balmanoukian; Charu Aggarwal; Leora Horn; Amita Patnaik; Matthew Gubens; Suresh S Ramalingam; Enriqueta Felip; Jonathan W Goldman; Cathie Scalzo; Erin Jensen; Debra A Kush; Rina Hui
Journal:  J Clin Oncol       Date:  2019-06-02       Impact factor: 44.544

10.  Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience.

Authors:  Corey J Hobbs; Stephen J Ko; Nitesh N Paryani; Joseph M Accurso; Kenneth R Olivier; Yolanda I Garces; Sean S Park; Christopher L Hallemeier; Steven E Schild; Sujay A Vora; Jonathan B Ashman; William G Rule; Johnny R Bowers; Michael G Heckman; Nancy N Diehl; Robert C Miller
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2017-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.